Bionano Genomics, Inc. (BNGO) vs Neuphoria Therapeutics Inc. (NEUP)
A side-by-side comparison of Bionano Genomics, Inc. and Neuphoria Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BNGO
Bionano Genomics, Inc.
$1.47HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
NEUP
Neuphoria Therapeutics Inc.
$3.50HealthcareDelayed quote: Oct 6, 2026, 11:03 AM EDT
Total return — BNGO vs NEUP
growth of $100 · dividends reinvested · last 5yBNGO -99.9% (-76.4%/yr)NEUP -98.0% (-54.5%/yr)NEUP compounded faster over this window
Log scale — wide-divergence pair
BNGO NEUP
BNGO vs NEUP: by the numbers
- •NEUP is the larger company ($19M vs $17M market cap).
- •Both run net losses; BNGO's is the smaller (-106.58% vs -1578.40% net margin).
- •BNGO grew revenue faster over the past five years (17.97% vs 11.12% CAGR).
Metrics side by side
Valuation
| Metric | BNGO | NEUP |
|---|---|---|
| P/S ratio | 0.56 | 16.11 |
| P/B ratio | 0.53 | 0.77 |
Profitability
| Metric | BNGO | NEUP |
|---|---|---|
| Gross margin | 21.95% | 43.54% |
| Operating margin | -116.95% | -835.53% |
| Net margin | -106.58% | -1578.40% |
| ROE | -101.76% | -75.34% |
| ROIC | -85.72% | -49.83% |
Growth (annualized)
| Metric | BNGO | NEUP |
|---|---|---|
| Revenue CAGR (5Y) | 17.97% | 11.12% |
| Total return CAGR (5Y) | -78.37% | N/A |
Frequently asked
- Which has grown faster, BNGO or NEUP?
- Over the past five years, BNGO grew revenue faster — BNGO at a 17.97% CAGR versus NEUP at 11.12%.
Go deeper
Dig into the metrics
Bionano Genomics ROENeuphoria Therapeutics ROEBionano Genomics operating marginNeuphoria Therapeutics operating marginBionano Genomics revenue growthNeuphoria Therapeutics revenue growthBionano Genomics free cash flowNeuphoria Therapeutics free cash flow
Bionano Genomics & Neuphoria Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.